OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ruddy on the Use of GnRH Agonists in Breast Cancer

May 10th 2022

Kathryn Ruddy, MD, discusses the use of GnRH agonists in breast cancer.

Dr. Furman on Current Treatment Options in CLL

May 10th 2022

Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.

Dr. Heyman on the ALPINE Trial in CLL

May 10th 2022

Benjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.

Dr. Ma on Utilizing Zanabrutinib in CLL

May 10th 2022

Shuo Ma, MD, PhD, discusses the utilization of zanubrutinib in chronic lymphocytic leukemia.

Dr. McArthur on the FDA Approval of Second-Line Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 6th 2022

Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.

Dr. Partridge on the Utilization of GnRH Agonists in Breast Cancer

May 6th 2022

Ann H. Partridge, MD, MPH, discusses the utilization of GnRH agonists to preserve ovarian function in premenopausal patients with breast cancer.

Dr. Spira on the Examination of RTX-240 in a Phase 1 Trial with Solid Tumors

May 6th 2022

Alexander I. Spira, MD, PhD, FACP, discusses the examination of RTX-240 in a phase 1 trial with solid tumors.

Dr. Verstovsek on the Future of ALK2 Inhibitors in Myelofibrosis

May 4th 2022

Srdan Verstovsek, MD, PhD, discusses the future of ALK2 inhibitors in myelofibrosis.

Dr. Obeid on the KATHERINE Trial in HER2-Positive Breast Cancer

May 4th 2022

Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.

Dr. Kalinsky on Updates from the TAILORx Trial in HR-Positive/HER2-Negative Breast Cancer

May 4th 2022

Kevin Kalinsky, MD, MS, discusses updates from the phase 3 TAILORx trial in patients with hormone receptor–positive or HER2-negative breast cancer with node-negative disease.

Dr. Mesa on the Future of JAK Inhibitor Therapy in Myelofibrosis

May 4th 2022

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

Dr. Monk on the Growing Role of Checkpoint Inhibitors in Cervical Cancer

May 4th 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the growing role of checkpoint inhibitors in cervical cancer.

Dr. Mesa on Determinants of Disparities in Cancer Care

May 3rd 2022

Ruben A. Mesa, MD, discusses various determinants of disparities in cancer care.

Dr. Deol on CAR T-Cell Therapy in Earlier Lines of Therapy in Cancer Care

May 3rd 2022

Abhinav Deol, MD, discusses shifting CAR T-cell therapy to earlier lines of therapy in cancer care.

Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL

May 3rd 2022

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Verstovsek on Addressing Anemia in Patients with Myelofibrosis

May 3rd 2022

Srdan Verstovsek, MD, PhD, discusses addressing anemia in patients with myelofibrosis.

Dr. Grivas on the TROPHY U-01 Trial in Urothelial Cancer

May 2nd 2022

Petros Grivas, MD, PhD, discusses the phase 2 TROPHY U-01 trial in metastatic urothelial cancer.

Dr. Iacovelli on Key Takeaways from the ARIES Trial in Urothelial Cancer

May 2nd 2022

Roberto Iacovelli, MD, PhD, discusses the key takeaways of the phase 2 ARIES trial in urothelial cancer.

Dr. Munver on the Approval of Mitomycin Gel in Urothelial Cancer

April 29th 2022

Ravi Munver, MD, discusses the approval of mitomycin gel in urothelial cancer.

Dr. Olawaiye on How to Address Disparities in Cancer Care

April 29th 2022

Alexander B. Olawaiye, MD, discusses how to address disparities in cancer care.